Bristol-Myers Squibb Co (BMY)
43.99
+0.29
(+0.66%)
USD |
NYSE |
May 03, 16:00
43.97
-0.02
(-0.05%)
After-Hours: 20:00
Bristol-Myers Squibb Net Income (Annual): 8.025B for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 8.025B |
December 31, 2022 | 6.327B |
December 31, 2021 | 6.994B |
December 31, 2020 | -9.015B |
December 31, 2019 | 3.439B |
December 31, 2018 | 4.92B |
December 31, 2017 | 1.007B |
December 31, 2016 | 4.457B |
December 31, 2015 | 1.565B |
December 31, 2014 | 2.004B |
December 31, 2013 | 2.563B |
December 31, 2012 | 1.96B |
December 31, 2011 | 3.709B |
December 31, 2010 | 3.102B |
December 31, 2009 | 10.61B |
December 31, 2008 | 5.247B |
December 31, 2007 | 2.165B |
December 31, 2006 | 1.585B |
December 31, 2005 | 3.00B |
Date | Value |
---|---|
December 31, 2004 | 2.388B |
December 31, 2003 | 3.106B |
December 31, 2002 | 2.137B |
December 31, 2001 | 4.834B |
December 31, 2000 | 4.711B |
December 31, 1999 | 4.167B |
December 31, 1998 | 3.141B |
December 31, 1997 | 3.205B |
December 31, 1996 | 2.85B |
December 31, 1995 | 1.812B |
December 31, 1994 | 1.842B |
December 31, 1993 | 1.959B |
December 31, 1992 | 1.962B |
December 31, 1991 | 2.056B |
December 31, 1990 | 1.748B |
December 31, 1989 | 747.00M |
December 31, 1988 | 1.254B |
December 31, 1987 | 1.068B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-9.015B
Minimum
2020
8.025B
Maximum
2023
3.154B
Average
6.327B
Median
2022
Net Income (Annual) Benchmarks
Amgen Inc | 6.717B |
Gilead Sciences Inc | 5.665B |
Johnson & Johnson | 35.15B |
Karuna Therapeutics Inc (DELISTED) | -433.68M |
2seventy bio Inc | -217.57M |